Robin Hayes
FDA Approves First At-Home HPV Test as Alternative to In-Office Pap Smear
On May 11, 2025, the U.S. Food and Drug Administration (FDA) granted approval for the country’s first at-home human papillomavirus (HPV) test designed as an optional alternative to the traditional in-office Pap smear. Manufactured by MedAware Diagnostics (a subsidiary of Hackensack Meridian Health), the test enables individuals with a cervix to collect their own vaginal sample via a soft, sponge-like swab. Following a telehealth consultation, patients mail their specimens to a central laboratory for HPV analysis. Those who receive a positive result are promptly referred for an in-office Pap smear and follow-up care, while patients testing negative can safely defer further screening for three to five years in accordance with established guidelines.
· 6 min read

